We are live on ! Find out more
IVM

InterWest Venture Management Portfolio holdings

AUM $20.6M
1-Year Est. Return 48.5%
This Fund
S&P 500
This Quarter Est. Return
+15.93%
1 Year Est. Return
+48.5%
3 Year Est. Return
-57.65%
5 Year Est. Return
-76.52%
10 Year Est. Return
–
AUM
$470M
AUM Growth
+$51M
Cap. Flow
-$5.36M
Cap. Flow %
-1.14%
Top 10 Hldgs %
99.79%
Holding
14
New
–
Increased
–
Reduced
1
Closed
2

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
OCRX
Ocera Therapeutics, Inc.
OCRX
+$2.62M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$2.45M
3
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$285K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSRO
1
DELISTED
TESARO, Inc.
TSRO
$311M 66.12%
2,021,403
– –
GKOS icon
2
Glaukos
GKOS
$8.92B
$52.2M 11.11%
1,018,362
– –
HIND
3
Vyome Holdings
HIND
$14M
– –
0
– –
MGNX icon
4
MacroGenics
MGNX
$254M
$20M 4.25%
1,074,316
– –
EIGR
5
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$18.3M 3.89%
53,320
– –
CDTX
6
DELISTED
Cidara Therapeutics
CDTX
$10.6M 2.25%
67,841
– –
AGTC
7
DELISTED
Applied Genetic Technologies Corporation
AGTC
$10M 2.13%
1,452,216
– –
PRTK
8
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$9.86M 2.1%
512,366
– –
IVTY
9
DELISTED
Invuity, Inc
IVTY
$8.59M 1.83%
1,080,272
– –
KALV
10
DELISTED
KalVista Pharmaceuticals
KALV
$2.58M 0.55%
329,942
– –
LITS
11
Lite Strategy Inc
LITS
$33.2M
$940K 0.2%
29,020
– –
XENE icon
12
Xenon Pharmaceuticals
XENE
$6.36B
$33K 0.01%
8,293
-311,768
-97% -$2.45M
RETA
13
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-13,058
Closed -$285K
OCRX
14
DELISTED
Ocera Therapeutics, Inc.
OCRX
– –
-1,248,064
Closed -$2.62M

Similar funds

RCP
Rho Capital Partners New York $20.4M AUM
LUGPI
Lightspeed Ultimate General Partner IX Menlo Park, California $20.3M AUM 4.78% 1-Year Est. Return
SIC
Starr International Company Zug, Switzerland $19.9M AUM 39.69% 1-Year Est. Return
DOS
David O. Sacks $19.8M AUM 4.02% 1-Year Est. Return
AA
Antipodean Advisors New York $19.5M AUM 6.21% 1-Year Est. Return
CVSCT
C.V. Starr & Co Trust New York $19.4M AUM 28.57% 1-Year Est. Return
VNB
Virginia National Bank Charlottesville, Virginia $21.9M AUM 12.04% 1-Year Est. Return
BEP
Brookside Equity Partners Stamford, Connecticut $22.5M AUM 62.43% 1-Year Est. Return

InterWest Venture Management's Q1 2017 Portfolio in Review

As of Q1 2017, InterWest Venture Management held 14 positions worth $470M, up 12% from $419M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

InterWest Venture Management's Q1 2017 filing shows 1 reduced and 2 closed positions. The largest sale was Ocera Therapeutics, Inc., an estimated $2.62M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

  • InterWest Venture Management's biggest Q1 2017 reduction was Xenon Pharmaceuticals, cutting an estimated $2.45M.
  • InterWest Venture Management fully exited Ocera Therapeutics, Inc. in Q1 2017, selling an estimated $2.62M.
  • InterWest Venture Management's ten largest holdings make up 100% of its $470M portfolio in Q1 2017.
  • InterWest Venture Management opened 0 new positions and closed 2 in Q1 2017.
  • InterWest Venture Management's portfolio value rose 12% quarter-over-quarter to $470M.

Based on InterWest Venture Management's 13F filing for Q1 2017, filed 14 Apr 2017.